Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults
- First Posted Date
- 2009-10-15
- Last Posted Date
- 2014-02-12
- Lead Sponsor
- Exsulin Corporation
- Target Recruit Count
- 23
- Registration Number
- NCT00995540
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
๐จ๐ฆMcGill University - Montreal General Hospital, Montreal, Quebec, Canada
Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- Drug: INGAP-PeptideDrug: placebo
- First Posted Date
- 2003-10-23
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Exsulin Corporation
- Target Recruit Count
- 126
- Registration Number
- NCT00071422
- Locations
- ๐บ๐ธ
VA Hospital UCSD, San Diego, California, United States
๐บ๐ธDiabetes and Endocrine Associates, La Jolla, California, United States
๐บ๐ธDiablo Clinical Research, Walnut Creek, California, United States
Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Insulin-Dependent
- Interventions
- Drug: placeboDrug: INGAP-Peptide
- First Posted Date
- 2003-10-23
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Exsulin Corporation
- Target Recruit Count
- 63
- Registration Number
- NCT00071409
- Locations
- ๐บ๐ธ
Diablo Clinical Research, Walnut Creek, California, United States
๐บ๐ธSpringfield Diabetes and Endocrine Center, Springfield, Illinois, United States
๐บ๐ธMedStar Clinical Research Center, Washington, District of Columbia, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath